SCHEMBL3427705

SCHEMBL3427705

O=C(NC1CCCC1)c1cccnc1

nearest known ligand 0.97

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
L3MBTL1 Q9Y468 3/20 0.70
HTT P42858 2/20 0.67
GRM5 P41594 2/20 0.66
MAPT P10636 1/20 0.66
POLB P06746 1/20 0.58
TSHR P16473 2/20 0.58
RAB9A P51151 2/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
LMNA P02545 1/20 0.56
NPC1 O15118 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10143960 0.98 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
SCHEMBL4414127 0.98 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
SCHEMBL3427969 0.97 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
SCHEMBL1116630 0.93 ALDH1A1 (0.78) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
Piperidine SCHEMBL3246198 0.90 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
SCHEMBL27368115 0.90 GRM5 (0.62) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
SCHEMBL5783791 0.88 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
SCHEMBL12424958 0.86 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
SCHEMBL5083468 0.86 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5
SCHEMBL19691212 0.86 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2L3MBTL1HTTGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897866-B1 AN ANTIMICROBIAL COMPOSITION UNILEVER IP HOLDINGS B V (NL) 2025-11-05 EP claimed
US-12311044-B2 Antimicrobial composition CONOPCO, INC. (US) 2025-05-27 US claimed
CN-119654130-A Use of a composition for enhancing night repair related functions of skin 联合利华知识产权控股有限公司 2025-03-18 CN claimed
CN-117915890-A Deodorant composition 联合利华知识产权控股有限公司 2024-04-19 CN claimed
CN-113242751-B Antimicrobial compositions 联合利华知识产权控股有限公司 2023-09-19 CN claimed
CN-111787903-B Disinfectant composition 联合利华知识产权控股有限公司 2023-08-15 CN claimed
US-20220087914-A1 AN ANTIMICROBIAL COMPOSITION CONOPCO, INC., D/B/A UNILEVER (US) 2022-03-24 US claimed
EP-3897866-A1 AN ANTIMICROBIAL COMPOSITION Unilever IP Holdings B.V. (NL) 2021-10-27 EP claimed
CN-113242751-A Antimicrobial compositions 联合利华知识产权控股有限公司 2021-08-10 CN claimed
WO-2020126347-A1 AN ANTIMICROBIAL COMPOSITION UNILEVER N.V. (NL) 2020-06-25 WO claimed
EP-3897866-B1 AN ANTIMICROBIAL COMPOSITION UNILEVER IP HOLDINGS B V (NL) 2025-11-05 EP disclosed
US-12311044-B2 Antimicrobial composition CONOPCO, INC. (US) 2025-05-27 US disclosed
CN-119654130-A Use of a composition for enhancing night repair related functions of skin 联合利华知识产权控股有限公司 2025-03-18 CN disclosed
CN-113242751-B Antimicrobial compositions 联合利华知识产权控股有限公司 2023-09-19 CN disclosed
CN-111787903-B Disinfectant composition 联合利华知识产权控股有限公司 2023-08-15 CN disclosed
WO-2008073461-A2 ION CHANNEL MODULATORS WYETH (US) 2008-06-19 WO disclosed
US-20060276516-A1 Nicotinamide Derivatives Useful as p38 Inhibitors SMITHKLINE BEECHAM CORPORATION 2006-12-07 US disclosed
US-20060264479-A1 Nicotinamide Derivatives Useful as p38 Inhibitors SMITHKLINE BEECHAM CORPORATION 2006-11-23 US disclosed
US-7125898-B2 Nicotinamide derivatives useful as p38 inhibitors. SMITHKLINE BEECHAM CORPORATION (US) 2006-10-24 US disclosed
US-20050176964-A1 Nicotinamide derivatives useful as p38 inhibitors GLAXOSMITHKLINE LLC 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12311044-B2 Antimicrobial composition DPM1, THPO, FPR1 ALDH1A1 2349/4885SMN1; SMN2 4342/4885L3MBTL1 2696/4885
US-20060264479-A1 Nicotinamide Derivatives Useful as p38 Inhibitors MAPK1, MAPK7, MAPK6 ALDH1A1 723/4885SMN1; SMN2 1259/4885L3MBTL1 4018/4885
US-20060276516-A1 Nicotinamide Derivatives Useful as p38 Inhibitors MAPK1, MAPK7, MAPK6 ALDH1A1 723/4885SMN1; SMN2 1259/4885L3MBTL1 4018/4885
US-20220087914-A1 AN ANTIMICROBIAL COMPOSITION THPO, BROX, FPR1 ALDH1A1 2160/4885SMN1; SMN2 4373/4885L3MBTL1 2800/4885
US-20050176964-A1 Nicotinamide derivatives useful as p38 inhibitors MAPK1, MAPK7, MAPK6 ALDH1A1 723/4885SMN1; SMN2 1259/4885L3MBTL1 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.